Targeted immunotherapy for acute myeloid leukemia

Best Practice and Research: Clinical Haematology

Volumn 24, Issue 4, 2011, Pages 533-540

  Vasu, Sumithira ^a,b   Caligiuri, Michael A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

acute myeloid leukemia; allogeneic; AML; graft versus leukemia; GVL; hematopoietic stem cell transplantation; HSCT; IL 2; interleukin 2; killer immunoglobulin like receptors; KIR; natural killer; NK; T cell

Indexed keywords

ANTILEUKEMIC AGENT; CD123 ANTIGEN; CD33 ANTIGEN; CD47 ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERLEUKIN 15; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MELANOMA VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1 7F9; MONOCLONAL ANTIBODY CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CYTOKINE PRODUCTION; CYTOLYSIS; DRUG EFFICACY; DRUG TARGETING; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LEUKEMIA REMISSION; MELANOMA; MELANOMA CELL; NATURAL KILLER CELL; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

EID: 82355170660     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2011.09.001     Document Type: Review

References (39)

1. H.J. Kolb Graft-versus-leukemia effects of transplantation and donor lymphocytes Blood 112 2008 4371 4383
2. V. Gupta, M.S. Tallman, and D.J. Weisdorf Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns Blood 117 2011 2307 2318
3. K. Vincent, D.C. Roy, and C. Perreault Next-generation leukemia immunotherapy Blood 118 2011 2951 2959
4. R.M. Stone, D.J. DeAngelo, and A. Janosova Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission Am J Hematol 83 2008 771 777
5. M.R. Baer, S.L. George, and M.A. Caligiuri Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: cancer and Leukemia Group B Study 9720 J Clin Oncol 26 2008 4934 4939
6. M.A. Caligiuri Human natural killer cells Blood 112 2008 461 469
7. P. Porcu, C.F. Eisenbeis, and R.P. Pelletier Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration Blood 100 2002 2341 2348
8. S. Bauer, V. Groh, and J. Wu Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA Science 285 1999 727 729
9. D.H. Raulet, and N. Guerra Oncogenic stress sensed by the immune system: role of natural killer cell receptors Nat Rev Immunol 9 2009 568 580
10. V. Groh, J. Wu, and C. Yee Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation Nature 419 2002 734 738 (Pubitemid 35177960)
11. S.A. Quezada, K.S. Peggs, and T.R. Simpson Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication Immunol Rev 241 2011 104 118
12. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
13. L. Ruggeri, M. Capanni, and E. Urbani Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2002 2097 2100 (Pubitemid 34229476)
14. J.A. Olson, D.B. Leveson-Gower, and S. Gill NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects Blood 115 21 2010 4293 4301
15. M. Noval Rivas, M. Hazzan, and K. Weatherly NK cell regulation of CD4 T cell-mediated graft-versus-host disease J Immunol 184 2010 6790 6798
16. M. Uhrberg, N.M. Valiante, and B.P. Shum Human diversity in killer cell inhibitory receptor genes Immunity 7 6 1997 753 763 (Pubitemid 28064889)
17. P. Parham MHC class I molecules and KIRs in human history, health and survival Nat Rev Immunol 5 3 2005 201 214 (Pubitemid 40364822)
18. S. Cooley, E. Trachtenberg, and T.L. Bergemann Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia Blood 113 2009 726 732
19. S. Cooley, D.J. Weisdorf, and L.A. Guethlein Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia Blood 116 2010 2411 2419
20. S. Sivori, S. Carlomagno, and M. Falco Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT Blood 117 2011 4284 4292
21. D. Pende, S. Marcenaro, and M. Falco Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity Blood 113 2009 3119 3129
22. A. Moretta, F. Locatelli, and L. Moretta Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias Immunol Rev 224 2008 58 69
23. J.S. Miller, Y. Soignier, and A. Panoskaltsis-Mortari Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 105 2005 3051 3057
24. J.E. Rubnitz, H. Inaba, and R.C. Ribeiro NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia J Clin Oncol 28 2010 955 959
25. A. Curti, L. Ruggeri, and A. D'Addio Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high-risk acute myeloid leukemia patients Blood 2011 Jul 25 [Epub ahead or print]
26. F. Romagne, P. Andre, and P. Spee Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells Blood 114 2009 2667 2677
27. N. Vey A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1-7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML): clinical and immunological effects of a single dose followed by repeated dosing Blood 114 2009 632
28. M.E. Keir, M.J. Butte, and G.J. Freeman PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704 (Pubitemid 351600389)
29. Q. Zhou, M.E. Munger, and S.L. Highfill Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia Blood 116 2010 2484 2493
30. C. Berger, M. Berger, and R.C. Hackman Safety and immunologic effects of IL-15 administration in nonhuman primates Blood 114 2009 2417 2426
31. S. Roychowdhury, K.F. May, and K.S. Tzou Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2 Cancer Research 64 2004 8062 8067 (Pubitemid 39446944)
32. B. Foley, S. Cooley, and M.R. Verneris NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions Blood 118 2011 2784 2792
33. C. Stein, C. Kellner, and M. Kugler Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells Br J Haematol 148 2010 879 889
34. R. Majeti, M.P. Chao, and A.A. Alizadeh CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells Cell 138 2009 286 299
35. X. Zhao, S. Singh, and C. Pardoux Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia Haematologica 95 2010 71 78
36. B. Stahnke, T. Thepen, and M. Stocker Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes Mol Cancer Ther 7 2008 2924 2932
37. E.H. Estey, P.F. Thall, and F.J. Giles Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside Blood 99 2002 4343 4349 (Pubitemid 34627199)
38. M. Levis FLT3/ITD AML and the law of unintended consequences Blood 117 2011 6987 6990
39. T. Sato, X. Yang, and S. Knapper FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo Blood 117 2011 3286 3293